MedTrace Logo

A Multicenter Real World Study of Kanglaite for Cancer Cachexia

NCT03631459 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100000

Last updated 2018-08-21

No results posted yet for this study

Summary

A prospective, multi-center real-world study of the effectiveness and safety of Kanglaita Injection/Capsule in Chinese patients with cancer cachexia

Conditions

  • Cancer Cachexia

Interventions

DRUG

Kanglaite Injection/Capsules

Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles

Sponsors & Collaborators

  • NanJing PLA 81 Hospital

    collaborator OTHER

  • LinkDoc Technology (Beijing) Co. Ltd.

    collaborator INDUSTRY

  • Zhejiang Kanglaite Pharmaceutical Co.Ltd

    lead OTHER

Principal Investigators

  • Shukui Qin, MD · NanJing PLA 81 Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2020-03-20
Completion
2020-07-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03631459 on ClinicalTrials.gov